One of the crueler aspects of biotech is that investors can be right
about a technology or drug, but still not make much money from it. Bad
deals, bad management, and mismanaged expectations can sometimes do harm
that even blockbuster drugs can't fix. While I don't think any of that
applies to ImmunoGen (IMGN), I do wonder how much value lies in this company's Targeted Antibody Payload (TAP) technology (basically the company's own antibody drug conjugate approach).
Please read more here:
Is ImmunoGen More Than T-DM1?
No comments:
Post a Comment